ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Whole-genome characterization of a colistin-resistant Klebsiella quasipneumoniae subsp. quasipneumoniae isolate from a urinary tract infection in Peshawar, Pakistan.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Klebsiella quasipneumoniae is a Gram-negative, non-motile, capsulated, facultative anaerobic rod within the K. pneumoniae species complex (KpSC) and is increasingly recognized as an opportunistic pathogen associated with bloodstream infections, urinary tract infections (UTIs), and other clinically significant conditions. Because it shares many phenotypic characteristics with K. pneumoniae, accurate diagnosis remains challenging in routine clinical settings, particularly in low-resource laboratories lacking access to molecular identification tools. In this study, we characterized the antimicrobial resistance (AMR) profile of a K. quasipneumoniae subsp. quasipneumoniae isolate obtained from a UTI case in Peshawar, Pakistan. The isolate exhibited a multidrug resistant (MDR) phenotype, with resistance to β-lactams, carbapenems, fluoroquinolones, and colistin (MIC 4 µg/mL), while remaining susceptible to aminoglycosides (amikacin and gentamicin) and tigecycline (MIC 2 µg/mL). Whole-genome sequencing (WGS) identified chromosomally encoded AMR determinants, including blaOKP-A-8, oqxAB, and fosA6, with no identifiable plasmid replicons detected. Multiple nonsynonymous mutations were observed in mgrB, pmrA/B, phoP/Q, lpxM, ompK35/36, and gyrA/parC, which have been previously associated with resistance phenotypes; however, their functional contribution in this isolate was inferred from genomic data and not experimentally validated. Virulence-associated loci such as fim, ecp, entB, and fepC were present, consistent with a classical (non-hypervirulent) phenotype. Phylogenomic analysis positioned the isolate (Kq1223) on a distinct branch relative to publicly available genomes, but given that this study is based on a single isolate, no definitive conclusions regarding regional lineage or evolutionary patterns can be established. The allelic profile identified by multilocus sequence typing (MLST) has not been previously reported and may represent an unassigned sequence type pending formal database validation. The presence of chromosomally mediated MDR, including colistin resistance, highlights potential therapeutic challenges and underscores the importance of accurate species identification and expanded genomic surveillance of Klebsiella species in clinical microbiology, particularly in resource limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.